Table of Contents
ISRN Rheumatology
Volume 2013, Article ID 357904, 9 pages
Review Article

Oral Janus Kinase Inhibitor for the Treatment of Rheumatoid Arthritis: Tofacitinib

1Internal Medicine, SEGi University, No. 9 Jalan Teknologi, Taman Sains Selangor, Kota Damansara, PJU 5, 47810 Petaling Jaya, Selangor, Malaysia
2Community Medicine, Melaka Manipal Medical College, Jalan Batu Hampar, Bukit Baru, Malacca 75150, Malaysia
3Ophthalmology, Melaka Manipal Medical College, Jalan Batu Hampar, Bukit Baru, Malacca 75150, Malaysia
4Diagnostic Radiology, Defense Service General Hospital, Naypyitaw, Myanmar

Received 30 May 2013; Accepted 29 June 2013

Academic Editors: O. Sander and P. Voulgari

Copyright © 2013 Han Ni et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Since the introduction of immune modulators in the treatment of rheumatoid arthritis (RA), there has been hope that orally effective biologic agents would be developed. Tofacitinib, a Janus kinase inhibitor, has become the first oral biologic to receive approval for use in active RA patients. This paper reviews the efficacy and safety profile of Tofacitinib at dosages of 5 mg and 10 mg twice daily. Remarkable improvement in terms of ACR 20 response and HAQ-DI score was noted at month 3 and month 6. DAS 28-4 ESR < 2.6 achievement was noticeably obvious at month 6 for both dosages. No significant serious adverse events, serious infections, neutropenia, or anaemia were observed compared to placebo. In fact, Tofacitinib 5 mg was even found to have significant protective effect of anaemia in the meta-analysis ( ). Tofacitinib has a noticeable efficacy in controlling disease activity in RA with a manageable safety profile. However, longer studies are needed for its long-term safety profile.